Olaparib in Patients With HRD Malignant Mesothelioma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Olaparib in Patients With HRD Malignant Mesothelioma — Stella

Home/Mesothelioma/

View on ClinicalTrials.gov

Recruiting

Back to Mesothelioma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

University of Chicago Medical Center, Chicago, Illinois

Key details

Phase

Safety & dosing

Sponsor

University of Chicago

Collaborators

AstraZeneca

Enrollment target

~56 participants

Started

February 2021

Primary completion

April 2028

Age range

18 Years and older

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.